![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Bristol Myers Squibb’s Inrebic Approved in Canada for Myelofibrosis
Bristol Myers Squibb’s Inrebic Approved in Canada for Myelofibrosis
![](https://www.fdanews.com/ext/resources/test/Drug-Images4/Bristol_Meyers_Squibb_logo.jpg?t=1444401319&width=430)
September 22, 2020
Health Canada has approved Bristol Myers Squibb’s Inrebic (fedratinib) for the treatment of certain patients with enlarged spleen caused by myelofibrosis, a rare bone marrow cancer.
The agency specifically approved the drug for patients with intermediate-2 or high-risk primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.
The approval was based on results of two clinical trials in which Inrebic demonstrated a clinically meaningful reduction in spleen volume for patients with myelofibrosis.
The FDA approved Inrebic for myelofibrosis patients in August 2019.
Upcoming Events
-
21Oct